Culmination Bio Inc

CEO, Lincoln Nadauld, sat down w/ @dslevine on The Bio Report to discuss how real-world data is transforming drug discovery & clinical trials. Tune in to learn how Culmination Bio’s 40+ years of data is driving healthcare innovation:tinyurl.com/snbj6fyt

"To have clinical, genomic, and biospecimen data, all linked in a continuous fashion over decades, & from a single source, is unusual." CEO Lincoln Nadauld sat down w/ @Merck @IyaKhalil to talk unusual data for understanding biology in @DrugDiscoverDev : bit.ly/3X87m8N

Currently, 1 in 5 people develop cancer in their lifetime. To better understand cancer and make care determinations, @BillionToOneInc is developing and validating diagnostics with Culmination Bio’s extensive patient base. More via HIT Consultant: bit.ly/4aBGIZm

In a 24-month R&D partnership, @Merck is leveraging our unique ability to build retrospective and prospective deidentified multi-modal datasets to study a variety of autoimmune diseases. More details from Joesph Keenan in @FierceBiotech: bit.ly/3SkAXrQ CC: @AGKootenay

“To Lincoln Nadauld, the $10 million raised by his fledgling company Culmination Bio in its first financing round is market validation of the industry-wide need for detailed, longitudinal data…” More from @Ch_Hops in Precision Medicine Online: bit.ly/3RwjDkp

Now backed with $10 million from @Amgen and @Merck, we’re building the largest disease-agnostic patient data intelligence platform to solve the data gap in pharma. Read about our patient data repository from @erinbrodwin via @axios: axios.com/pro/health-tec…

We're excited to announce that Dr. Lincoln Nadauld will be speaking at the Illumina Genomics Forum alongside other experts in discussing the use of genomics to advance precision health. Dr. Nadauld will be speaking on the power of multimodal data for healthcare innovation.